SCHEMBL2926028

SCHEMBL2926028

O=C(O)CCCOC1=COC(Cc2ccccc2)O1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.41
MAPK1 P28482 1/20 0.41
ADRA1A P35348 1/20 0.41
HDAC4 P56524 1/20 0.41
SLC6A3 Q01959 1/20 0.41
HDAC1 Q13547 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
FFAR1 O14842 3/20 0.40
MAPT P10636 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
FFAR4 Q5NUL3 3/20 0.38
PPARA Q07869 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5279461 0.85 ALOX15 (0.42) SMN1; SMN2FFAR1MAPTALDH1A1
SCHEMBL74038 0.80
SCHEMBL2946968 0.79 PDE3B (0.45) SMN1; SMN2ALDH1A1
SCHEMBL5007271 0.77 KDM4E (0.37) SMN1; SMN2MAPTHTTALDH1A1
SCHEMBL5156085 0.77 PSEN1 (0.46)
SCHEMBL5383390 0.74 PPARG (0.61) PPARA
SCHEMBL3524878 0.72 SLC6A2 (0.32) SLC6A3
SCHEMBL1698739 0.71 AKR1B1 (0.46) FFAR1KEAP1HTTLTB4R
SCHEMBL7911187 0.70 CPA3 (0.40) HDAC3MAPK1ADRA1AHDAC4SLC6A3
SCHEMBL230546 0.70 CTRB1 (0.36) KEAP1LTB4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2239012-A2 Pharmaceutical use of substituted amides High Point Pharmaceuticals, LLC (US) 2010-10-13 EP disclosed
EP-1615698-B1 NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF HIGH POINT PHARMACEUTICALS LLC (US) 2010-09-29 EP disclosed
US-20090264414-A1 Amide Derivatives and Pharmaceutical Use Thereof HIGH POINT PHARMACEUTICALS, LLC (US) 2009-10-22 US disclosed
US-20080108598-A1 Pharmaceutical use of substituted amides NOVO NORDISK A/S (DK) 2008-05-08 US disclosed
US-20060111366-A1 Pharmaceutical use of substituted amides NOVO NORDISK A/S (DK) 2006-05-25 US disclosed
EP-1615698-A2 NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF NOVO NORDISK A/S (DK) 2006-01-18 EP disclosed
WO-2004089470-A2 NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF NOVO NORDISK A/S (DK) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108598-A1 Pharmaceutical use of substituted amides HSD11B1, HSD3B1, HSD11B2 HDAC3 301/4885MAPK1 1770/4885ADRA1A 129/4885
US-20090264414-A1 Amide Derivatives and Pharmaceutical Use Thereof HSD11B1, HSD11B2, HSD3B1 HDAC3 194/4885MAPK1 1404/4885ADRA1A 184/4885
US-20060111366-A1 Pharmaceutical use of substituted amides HSD11B1, HSD3B1, HSD11B2 HDAC3 301/4885MAPK1 1770/4885ADRA1A 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.